TSVT - 2seventy bio, Inc. Stock Price, Fair Value and News

4.80USD-0.20 (-4.00%)Delayed

Market Summary

USD4.80-0.20

Delayed

-4.00%

TSVT Stock Price

View Fullscreen

TSVT RSI Chart

TSVT Valuation

Market Cap

246.7M

Price/Earnings (Trailing)

-1.11

Price/Sales (Trailing)

3.47

EV/EBITDA

-0.89

Price/Free Cashflow

-1.47

TSVT Price/Sales (Trailing)

TSVT Profitability

EBT Margin

-313.51%

Return on Equity

-107.61%

Return on Assets

-43.68%

Free Cashflow Yield

-68.12%

TSVT Fundamentals

TSVT Revenue

Revenue (TTM)

71.2M

Rev. Growth (Yr)

-70.12%

Rev. Growth (Qtr)

16.39%

TSVT Earnings

Earnings (TTM)

-223.2M

Earnings Growth (Yr)

-12.02%

Earnings Growth (Qtr)

7.3%

Breaking Down TSVT Revenue

Last 7 days

9.6%

Last 30 days

-5.1%

Last 90 days

-20%

Trailing 12 Months

-56.8%

How does TSVT drawdown profile look like?

TSVT Financial Health

Current Ratio

3.52

TSVT Investor Care

Shares Dilution (1Y)

2.40%

Diluted EPS (TTM)

-4.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	71.2M	0	0	0
2023	124.7M	147.3M	145.9M	100.4M
2022	51.0M	57.2M	51.4M	91.5M
2021	199.7M	151.3M	102.9M	54.5M
2020	0	0	146.2M	248.1M
2019	0	0	0	44.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 2seventy bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	eatwell victoria	acquired	-	-	42,500	chief financial officer
Apr 01, 2024	snow jessica	acquired	-	-	31,250	see remarks
Apr 01, 2024	baird william d iii	acquired	-	-	56,250	president and ceo
Mar 26, 2024	casdin capital, llc	bought	203,992	5.0998	40,000	-
Mar 25, 2024	casdin capital, llc	bought	1,673,990	5.0727	330,000	-
Mar 22, 2024	casdin capital, llc	bought	754,069	5.1166	147,377	-
Mar 21, 2024	casdin capital, llc	bought	1,470,990	4.9033	300,000	-
Mar 20, 2024	newton charles w.	acquired	-	-	16,600	-
Jan 08, 2024	baird william d iii	acquired	-	-	91,000	chief operating officer
Jan 08, 2024	leschly nick	acquired	-	-	235,000	president and ceo

Which funds bought or sold TSVT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	SkyView Investment Advisors, LLC	new	-	54,000	54,000	0.01%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-90.5	-783,111	105,796	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-8,282	27,018	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	11.11	43,000	155,000	-%
May 15, 2024	Woodline Partners LP	sold off	-100	-4,093,570	-	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-73.21	-154,605	78,110	-%
May 15, 2024	Bain Capital Life Sciences Investors, LLC	sold off	-100	-5,686,790	-	-%
May 15, 2024	Engine Capital Management, LP	unchanged	-	1,613,850	7,994,530	1.61%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	sold off	-100	-499,154	-	-%
May 15, 2024	DAFNA Capital Management LLC	reduced	-16.82	260,997	6,441,670	1.47%

Are Funds Buying or Selling TSVT?

Are funds buying TSVT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TSVT

No. of Funds

Unveiling 2seventy bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	4.99%	2,527,672	SC 13G/A
Feb 13, 2024	vanguard group inc	7.87%	3,985,770	SC 13G/A
Feb 12, 2024	morgan stanley	9.4%	4,748,235	SC 13G
Feb 08, 2024	goldman sachs group inc	8.8%	4,471,192	SC 13G
Feb 01, 2024	millennium management llc	4.7%	2,357,072	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	3,911,724	SC 13G/A
Jan 23, 2024	state street corp	1.93%	977,590	SC 13G/A
Nov 09, 2023	wellington management group llp	1.59%	802,967	SC 13G/A
Oct 10, 2023	state street corp	2.12%	1,069,125	SC 13G/A

Recent SEC filings of 2seventy bio, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 09, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 09, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Apr 03, 2024	3	Insider Trading

Peers (Alternatives to 2seventy bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

2seventy bio, Inc. News

Latest updates

2seventy bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	16.4%	12,435,000	10,684,000	12,034,000	36,048,000	41,621,000	56,177,000	13,408,000	13,482,000	8,429,000	16,035,000	19,257,000	7,328,000	11,901,000	15,167,500	18,434,000	-
Costs and Expenses	-10.0%	63,589,000	70,620,000	90,002,000	84,039,000	93,334,000	83,389,000	81,776,000	90,454,000	99,017,000	84,405,000	84,495,000	95,299,000	104,271,000	-	94,848,000	-
S&GA Expenses	-21.9%	12,659,000	16,201,000	13,004,000	19,489,000	20,720,000	18,701,000	19,610,000	17,278,000	23,861,000	24,481,000	22,996,000	21,402,000	24,627,000	-	22,105,000	-
R&D Expenses	-14.2%	43,931,000	51,217,000	51,315,000	59,980,000	68,246,000	60,144,000	58,155,000	64,557,000	65,879,000	50,223,000	61,131,000	63,692,000	77,571,000	-	72,253,000	-
EBITDA Margin	-44.9%	-2.99	-2.06	-1.19	-1.16	-1.65	-2.65	-5.44	-4.70	-5.38	-5.06	-1.04	-0.71	-0.54	-0.43	-2.11	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	7.3%	-52,673,000	-56,822,000	-71,638,000	-42,089,000	-47,021,000	-23,143,000	-67,879,000	-77,420,000	-85,711,000	-60,975,000	-60,001,000	-84,042,000	-87,196,000	-	-72,075,000	-
EBT Margin	-44.7%	-3.14	-2.17	-1.26	-1.22	-1.73	-2.78	-5.69	-4.97	-5.70	-5.36	-1.17	-0.79	-0.60	-0.48	-2.19	-
Net Income	7.3%	-52,673,000	-56,822,000	-71,638,000	-42,089,000	-47,021,000	-23,143,000	-67,879,000	-77,420,000	-85,711,000	-60,976,000	-60,001,000	-84,040,000	-87,196,000	-76,801,000	-72,075,000	-
Net Income Margin	-44.7%	-3.14	-2.17	-1.26	-1.22	-1.73	-2.78	-5.69	-4.97	-5.70	-5.36	-2.99	-2.12	-0.67	-0.48	-2.19	-
Free Cashflow	34.3%	-42,489,000	-64,708,000	-24,207,000	-36,683,000	-55,167,000	-58,727,000	-74,031,000	-49,125,000	-77,067,000	-58,235,000	-45,974,000	-43,120,000	-71,101,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-9.6%	511	565	641	706	742	657	709	787	852	760	193	313
Current Assets	-10.5%	213	238	277	334	390	301	349	384	413	292	25.00	25.00
Cash Equivalents	-23.9%	57.00	75.00	90.00	96.00	194	71.00	127	270	271	130	-	-
Net PPE	-34.2%	38.00	58.00	61.00	61.00	59.00	56.00	47.00	39.00	35.00	35.00	34.00	144
Goodwill	-	-	-	-	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	13.00
Liabilities	-2.1%	304	310	334	338	341	346	386	408	405	400	251	238
Current Liabilities	1.0%	60.00	60.00	68.00	67.00	77.00	80.00	80.00	99.00	106	98.00	106	76.00
Shareholder's Equity	-18.7%	207	255	306	367	401	310	323	379	447	360	-	75.00
Retained Earnings	-10.3%	-563	-511	-454	-382	-340	-293	-270	-202	-125	-39.49	-	-
Additional Paid-In Capital	0.6%	772	767	762	752	744	607	598	585	575	400	-	-
Shares Outstanding	1.6%	51.00	51.00	51.00	50.00	50.00	38.00	35.00	38.00	27.00	23.00	23.00	23.00
Float	-	-	-	-	508	-	-	-	497	613	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	34.2%	-41,877	-63,637	-21,463	-32,712	-49,088	-47,593	-60,613	-46,452	-73,482	-57,260	-43,350	-41,495	-64,750	-	-	-
Share Based Compensation	-5.4%	4,684	4,953	9,800	7,740	9,666	9,405	12,207	9,689	9,739	14,323	11,229	11,968	17,109	-	-	-
Cashflow From Investing	-54.4%	21,833	47,890	16,054	-64,881	44,798	-8,500	-82,295	49,799	44,749	1,014	-8,624	-3,625	-6,351	-	-	-
Cashflow From Financing	52.6%	386	253	-75.00	128	127,084	232	175	-4,277	170,099	186,694	51,974	45,120	71,101	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TSVT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Collaborative arrangement revenue	$ 4,714	$ 29,372
Total revenues	12,435	41,621
Operating expenses:
Research and development	43,931	68,246
Cost of manufacturing for commercial collaboration	3,269	3,654
Selling, general and administrative	12,659	20,720
Share of collaboration loss	1,230	0
Stock-based compensation expense	4,230	0
Cost of royalty and other revenue	0	641
Change in fair value of contingent consideration	(1,730)	73
Total operating expenses	63,589	93,334
Loss from operations	(51,154)	(51,713)
Interest income, net	2,861	2,049
Other income, net	646	2,643
Loss on assets held for sale	(5,026)	0
Loss before income taxes	(52,673)	(47,021)
Income tax (expense) benefit	0	0
Net loss	$ (52,673)	$ (47,021)
Net loss per share - basic (in dollars per share)	$ (1.01)	$ (1.08)
Net loss per share - diluted (in dollars per share)	$ (1.01)	$ (1.08)
Weighted-average number of common shares used in computing net loss per share - basic (in shares)	52,071,000	43,468,000
Weighted-average number of common shares used in computing net loss per share - diluted (in shares)	52,071,000	43,468,000
Other comprehensive (loss) income:
Other comprehensive (loss) income, net of tax benefit (expense) of $0.0 million and $0.0 million for the three months ended March 31, 2024 and 2023, respectively.	$ (132)	$ 927
Comprehensive loss	(52,805)	(46,094)
Service revenue
Revenue:
Revenue	7,721	10,826
Royalty and other revenue
Revenue:
Revenue	$ 0	$ 1,423

TSVT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 56,792	$ 74,958
Marketable securities	124,590	142,031
Assets held for sale	12,786	0
Prepaid expenses	6,697	7,365
Receivables and other current assets	11,977	13,411
Total current assets	212,842	237,765
Property, plant and equipment, net	38,234	58,150
Marketable securities	0	4,816
Intangible assets, net	6,417	6,594
Operating lease right-of-use assets	215,317	219,958
Restricted investments and other non-current assets	38,241	38,143
Total assets	511,051	565,426
Current liabilities:
Accounts payable	8,801	6,028
Accrued expenses and other current liabilities	22,263	25,688
Operating lease liability, current portion	13,006	12,660
Deferred revenue, current portion	16,336	15,403
Total current liabilities	60,406	59,779
Deferred revenue, net of current portion	2,450	3,918
Operating lease liability, net of current portion	240,071	244,013
Other non-current liabilities	685	2,416
Total liabilities	303,612	310,126
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized, 0 shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 200,000 shares authorized, 51,404 and 50,632 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	771,660	766,716
Accumulated other comprehensive loss	(336)	(204)
Accumulated deficit	(563,890)	(511,217)
Total stockholders’ equity	207,439	255,300
Total liabilities and stockholders’ equity	$ 511,051	$ 565,426

About 2seventy bio, Inc.

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Nick Leschly
WEBSITE	2seventybio.com
INDUSTRY	Biotechnology
EMPLOYEES	425

2seventy bio, Inc. Frequently Asked Questions

What is the ticker symbol for 2seventy bio, Inc.? What does TSVT stand for in stocks?

TSVT is the stock ticker symbol of 2seventy bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 2seventy bio, Inc. (TSVT)?

As of Fri May 17 2024, market cap of 2seventy bio, Inc. is 246.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TSVT stock?

You can check TSVT's fair value in chart for subscribers.

What is the fair value of TSVT stock?

You can check TSVT's fair value in chart for subscribers. The fair value of 2seventy bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 2seventy bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TSVT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 2seventy bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether TSVT is over valued or under valued. Whether 2seventy bio, Inc. is cheap or expensive depends on the assumptions which impact 2seventy bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TSVT.

What is 2seventy bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TSVT's PE ratio (Price to Earnings) is -1.11 and Price to Sales (PS) ratio is 3.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TSVT PE ratio will change depending on the future growth rate expectations of investors.